In the third episode of this series on MHT, We discuss the critical topic of the history of women and people with uteruses and ovaries in clinical research. The episode dives into how these groups were only regularly included in clinical studies from the 1990s and discusses the consequences of this.
We unpack the effects of this shift on menopausal hormone therapy, its efficacy, the risks involved, and the terms often involved in understanding related studies.
The episode stresses the importance of accurate and diverse data in medical research. Bree further explores the early stages of understanding menopause and the role of estrogen in treating its symptoms and discusses the challenges and scrutiny faced in the study of hormone therapy, especially about chronic disease prevention.
The episode emphasizes the careful consideration required in the decision to use Menopausal Hormone Therapy (MHT). Also, concerns surrounding bio-identical hormones are briefly touched upon. Finally, Bree encourages listeners to engage with the 'Pause to Go' community, sharing experiences and fostering support.
0:00 Decoding MHT Part 3
00:02 Introduction to the Podcast
00:44 The History of Women in Clinical Research
02:40 A Shoutout to Supporters ( Buy me a coffee. )
03:21 The Women's Health Movement in the 70s
05:17 The Fight for Inclusion in Clinical Trials
06:01 The Impact of the NIH Revitalization Act of 1993
08:32 The Journey from Exclusion to Inclusion
08:59 A Look Back at Hormone Herstory
09:35 The Controversy Surrounding Hormone Replacement Therapy
13:27 The Women's Health Initiative and Its Impact
16:02 The Current State of Menopausal Hormone Therapy
17:16 The Importance of Personalized Medicine
19:17 A Note on Bioidentical Hormones
19:46 Final Thoughts on Menopausal Hormone Therapy
20:19 Community Support and Engagement
21:08 Closing Remarks and Preview of Next Episode
References:
https://www.fda.gov/science-research/womens-health-research/gender-studies-product-development-historical-overview
https://www.fda.gov/science-research/womens-health-research/gender-studies-product-development-historical-overview
https://www.nbcnews.com/id/wbna16397237
Robert A. Wilson (1966). Feminine Forever. M. Evans and Company. ISBN 978-0-87131-049-1. OCLC 10373653. OL 5982073M.
Ziel H.K., Finkle W.D. Increased risk on endometrial carcinoma among users of conjugated estrogens. N. Engl. J. Med. 1975;293:1167–1170. doi: 10.1056/NEJM197512042932303. [PubMed] [CrossRef] [Google Scholar] [Ref list]
https://www.menopause.org/for-women/menopauseflashes/menopause-symptoms-and-treatments/hormone-therapy-benefits-risks
https://www.contemporaryobgyn.net/view/new-hormone-therapy-guidelines-from-the-north-american-menopause-society
https://www.hsph.harvard.edu/news/hsph-in-the-news/hormonal-therapy-menopause/
